How COVID-19 Has Impacted Clinical Trials for Chronic Lymphocytic Leukemia

Video

The COVID-19 Pandemic has changed immediate treatment for patients with chronic lymphocytic leukemia, but it is also impacting the clinical trials looking to improve the future treatment for these patients.

Many patients with chronic lymphocytic leukemia (CLL) rely on the outcomes of clinical trials that examine new ways to treat the disease. But with the new coronavirus (COVID-19) pandemic changing the way health care is provided around the country, so too is participation in these trials, according to Dr. Brian Koffman, the co-founder, executive vice president and chief medical officer of the CLL Society.

CURE® recently spoke with Koffman about how clinical trial participation has become more flexible over the course of the pandemic in an effort to keep immunocompromised individuals like those with CLL safe, by utilizing things like telemedicine and localized care to avoid exposure to the virus.

Transcription:

What I think we’ve learned from how COVID-19 has impacted the treatment schedules for people (with CLL) is that we can be more flexible. That there are a lot of things we can do with a telephone call or with a Zoom or Skype visit like we’re doing right now where we don’t have to get together in person.

Obviously, you can’t feel a lymph node over the TV or computer camera. But, a lot of stuff can be held. And what we’re seeing is that a lot of clinical trials are delaying, postponing some of the in-person meetings, letting people go (if they absolutely need lab work) to local labs to get things done, or just handling it with a telephone call.

Now, obviously if something is happening: you’re running a fever, the disease is taking off, there’s new symptoms, then you’re going to have to go to the clinic. But a lot of this stuff can be handled with a phone call or with a Zoom or Skype-type interview.

And that’s what’s happening for a lot of people, is they’re rescheduling. Because, really, if they can keep us vulnerable patients out of the hospital, the benefits of seeing the doctor personally may not outweigh the disadvantages or risks of walking through the hospital, which is where everyone who’s got a respiratory illness is going to be.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE